Rhenman Partners Asset Management Ab buys $4,453,686 stake in Nevro Corp (NVRO)

Nevro Corp (NVRO) : Rhenman Partners Asset Management Ab scooped up 34,300 additional shares in Nevro Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 54,300 shares of Nevro Corp which is valued at $4,453,686.Nevro Corp makes up approximately 0.71% of Rhenman Partners Asset Management Ab’s portfolio.

Other Hedge Funds, Including , Zurcher Kantonalbank (zurich Cantonalbank) boosted its stake in NVRO in the latest quarter, The investment management firm added 772 additional shares and now holds a total of 1,159 shares of Nevro Corp which is valued at $95,061.Kornitzer Capital Management Inc Ks reduced its stake in NVRO by selling 23,185 shares or 6.82% in the most recent quarter. The Hedge Fund company now holds 316,908 shares of NVRO which is valued at $26,208,292. Nevro Corp makes up approx 0.47% of Kornitzer Capital Management Inc Ks’s portfolio.Strs Ohio reduced its stake in NVRO by selling 9,366 shares or 96.9% in the most recent quarter. The Hedge Fund company now holds 300 shares of NVRO which is valued at $24,402.American Century Companies Inc boosted its stake in NVRO in the latest quarter, The investment management firm added 164,505 additional shares and now holds a total of 243,184 shares of Nevro Corp which is valued at $19,780,587. Nevro Corp makes up approx 0.02% of American Century Companies Inc’s portfolio.

Nevro Corp opened for trading at $82.09 and hit $82.8379 on the upside on Thursday, eventually ending the session at $82.08, with a gain of 0.07% or 0.06 points. The heightened volatility saw the trading volume jump to 2,34,328 shares. Company has a market cap of $2,325 M.

On the company’s financial health, Nevro Corp reported $-0.33 EPS for the quarter, beating the analyst consensus estimate by $ 0.32 according to the earnings call on May 9, 2016. Analyst had a consensus of $-0.65. The company had revenue of $41.65 million for the quarter, compared to analysts expectations of $34.72 million. The company’s revenue was up 331.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.57 EPS.

Many Wall Street Analysts have commented on Nevro Corp. Nevro Corp was Initiated by Piper Jaffray to “Overweight” on Jul 22, 2016. Nevro Corp was Initiated by Wells Fargo to “Outperform” on Jul 12, 2016.

Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Company’s Senza system creates electrical impulses from two hertz to 10 kilohertz including its HF10 therapy which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads a trial stimulator an implantable pulse generator (IPG) surgical tools a clinician laptop programmer a patient remote control and a mobile charger.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *